Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inflammatory stress response and hydroxyurea treatment in sickle cell disease
2008-005077-35Phase 4Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of hydroxyurea in sickle cell disease (SCD) (4 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Baseline inflammatory state, Natural stress response and 1 more. Started Aug 2008; status: active.
02
Drugs
hydroxyurea
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2008-005077-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005077-35.